Literature DB >> 27875674

Gene therapy approaches for the treatment of retinal disorders.

Lolita Petit1, Claudio Punzo1,2.   

Abstract

There is an impelling need to develop effective therapeutic strategies for patients with retinal disorders. Gleaning from the large quantity of information gathered over the past two decades on the mechanisms governing degeneration of the retina, it is now possible to devise innovative therapies based on retinal gene transfer. Different gene-based approaches are under active investigation. They include strategies to correct the specific genetic defect in inherited retinal diseases, strategies to delay the onset of blindness independently of the disease-causing mutations, and strategies to reactivate residual cells at late stages of the diseases. In this review, we discuss the status of application of these technologies, outlining the future therapeutic potential for many forms of retinal blinding diseases.

Entities:  

Mesh:

Year:  2016        PMID: 27875674      PMCID: PMC5142441     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  74 in total

Review 1.  AAV-mediated gene therapy in mouse models of recessive retinal degeneration.

Authors:  J-J Pang; L Lei; X Dai; W Shi; X Liu; A Dinculescu; J H McDowell
Journal:  Curr Mol Med       Date:  2012-03       Impact factor: 2.222

2.  RPE65 is the isomerohydrolase in the retinoid visual cycle.

Authors:  Gennadiy Moiseyev; Ying Chen; Yusuke Takahashi; Bill X Wu; Jian-Xing Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-22       Impact factor: 11.205

3.  AAV-mediated expression of CNTF promotes long-term survival and regeneration of adult rat retinal ganglion cells.

Authors:  S G Leaver; Q Cui; G W Plant; A Arulpragasam; S Hisheh; J Verhaagen; A R Harvey
Journal:  Gene Ther       Date:  2006-05-18       Impact factor: 5.250

4.  Thioredoxin rod-derived cone viability factor protects against photooxidative retinal damage.

Authors:  G Elachouri; I Lee-Rivera; E Clérin; M Argentini; R Fridlich; F Blond; V Ferracane; Y Yang; W Raffelsberger; Jun Wan; J Bennett; J-A Sahel; D J Zack; T Léveillard
Journal:  Free Radic Biol Med       Date:  2015-01-14       Impact factor: 7.376

5.  AAV-mediated Gene Therapy Halts Retinal Degeneration in PDE6β-deficient Dogs.

Authors:  Virginie Pichard; Nathalie Provost; Alexandra Mendes-Madeira; Lyse Libeau; Philippe Hulin; Kizito-Tshitoko Tshilenge; Marine Biget; Baptiste Ameline; Jack-Yves Deschamps; Michel Weber; Guylène Le Meur; Marie-Anne Colle; Philippe Moullier; Fabienne Rolling
Journal:  Mol Ther       Date:  2016-02-09       Impact factor: 11.454

6.  Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa.

Authors:  Shinichi Usui; Keiichi Komeima; Sun Young Lee; Young-Joon Jo; Shinji Ueno; Brian S Rogers; Zhihao Wu; Jikui Shen; Lili Lu; Brian C Oveson; Peter S Rabinovitch; Peter A Campochiaro
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

7.  Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa.

Authors:  Claudio Punzo; Karl Kornacker; Constance L Cepko
Journal:  Nat Neurosci       Date:  2008-12-07       Impact factor: 24.884

8.  Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial.

Authors:  Nicola G Ghazi; Emad B Abboud; Sawsan R Nowilaty; Hisham Alkuraya; Abdulrahman Alhommadi; Huimin Cai; Rui Hou; Wen-Tao Deng; Sanford L Boye; Abdulrahman Almaghamsi; Fahad Al Saikhan; Hassan Al-Dhibi; David Birch; Christopher Chung; Dilek Colak; Matthew M LaVail; Douglas Vollrath; Kirsten Erger; Wenqiu Wang; Thomas Conlon; Kang Zhang; William Hauswirth; Fowzan S Alkuraya
Journal:  Hum Genet       Date:  2016-01-29       Impact factor: 4.132

9.  Visual Acuity after Retinal Gene Therapy for Choroideremia.

Authors:  Thomas L Edwards; Jasleen K Jolly; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Graeme C Black; Andrew R Webster; Andrew J Lotery; Graham E Holder; Kanmin Xue; Susan M Downes; Matthew P Simunovic; Miguel C Seabra; Robert E MacLaren
Journal:  N Engl J Med       Date:  2016-04-27       Impact factor: 91.245

10.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

Authors:  Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra
Journal:  Lancet       Date:  2014-01-16       Impact factor: 79.321

View more
  5 in total

Review 1.  Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy.

Authors:  S P Simna; Zongchao Han
Journal:  Curr Gene Ther       Date:  2022       Impact factor: 4.676

Review 2.  Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?

Authors:  Karim Daliri; Alexander V Ljubimov; Seyedhossein Hekmatimoghaddam
Journal:  Int J Stem Cells       Date:  2017-11-30       Impact factor: 2.500

3.  Gene Therapy Restores Mfrp and Corrects Axial Eye Length.

Authors:  Gabriel Velez; Stephen H Tsang; Yi-Ting Tsai; Chun-Wei Hsu; Anuradha Gore; Aliaa H Abdelhakim; MaryAnn Mahajan; Ronald H Silverman; Janet R Sparrow; Alexander G Bassuk; Vinit B Mahajan
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

4.  Transduction Patterns of Adeno-associated Viral Vectors in a Laser-Induced Choroidal Neovascularization Mouse Model.

Authors:  Si Hyung Lee; Ye Seul Kim; Seung Kwan Nah; Hee Jong Kim; Ha Yan Park; Jin Young Yang; Keerang Park; Tae Kwann Park
Journal:  Mol Ther Methods Clin Dev       Date:  2018-01-31       Impact factor: 6.698

5.  Human MiniPromoters for ocular-rAAV expression in ON bipolar, cone, corneal, endothelial, Müller glial, and PAX6 cells.

Authors:  Andrea J Korecki; Jorge L Cueva-Vargas; Oriol Fornes; Jessica Agostinone; Rachelle A Farkas; Jack W Hickmott; Siu Ling Lam; Anthony Mathelier; Michelle Zhou; Wyeth W Wasserman; Adriana Di Polo; Elizabeth M Simpson
Journal:  Gene Ther       Date:  2021-02-02       Impact factor: 5.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.